

Endocrine hypertension- molecules and genes

Marie Freel
Senior Lecturer in Endocrinology
ABCD Spring Meeting
2nd May 2014








“An expert is someone who is more than 50 miles from home, has no responsibility for implementing the advice he gives and shows slides.”
Edwin Meese III

Plan

- Mineralocorticoid hypertension
- ‘Myths’ surrounding Primary Aldosteronism (PA)
- New developments in genetic aspects of PA

Mineralocorticoid actions



Post-receptor

Liddle's
syndrome

Abnormal receptor

Progesterone
induced
hypertension

Abnormal ligand

Cortisol (syndrome of
apparent mineralocorticoid
excess-SAME)
Mineralocorticoid
precursors (congenital
adrenal hyperplasia -CAH)

Normal ligand

Primary
Aldosteronism


Just another case of hypertension.....?

- 38 y female
- 6 years of hypertension, well controlled on ramipril
- But now BP difficult to control (162/95 mm/Hg) despite addition of amlodipine
- UE: Na 136, K 4.1 Chl 95 Ur 4.2 Cr 68
- Plasma aldosterone (supine) 395 pmol/L (100-400), plasma renin activity (PRC) 1.2 μ IU/ml (5-44.9)
 - Aldosterone to renin ratio (ARR) **329**


The myths of Primary Aldosteronism (PA)?

- PA is a rare cause of hypertension
- Serum potassium must be normal
- Plasma aldosterone must be elevated
- Making the diagnosis doesn't matter- just lower the blood pressure!

Prevalence of Primary Aldosteronism




Five Continents study: change in PA detection rate




The myths of Primary Aldosteronism (PA)?

- PA is a rare cause of hypertension
- Serum potassium must be normal
- Plasma aldosterone must be elevated
- Making the diagnosis doesn't matter- just lower the blood pressure!

Hypokalaemia and Primary Aldosteronism



Frequency of hypokalaemia in PA



The myths of Primary Aldosteronism (PA)?

- PA is a rare cause of hypertension
- Serum potassium must be normal
- Plasma aldosterone must be elevated
- Making the diagnosis doesn't matter- just lower the blood pressure!

PA or not PA?

- High ARR mainly due to low renin
- How does this differ from low-renin essential hypertension?
 - Subset of hypertensives with low PRA but normal aldosterone
 - Sodium sensitive, diuretic responsive
 - More common in elderly and black populations

Spectrum of relative aldosterone excess

**Bilateral
Adrenal
Hyperplasia**

LREH

**Essential
Hypertension**



**Sodium
intake**

**Genetic
predisposition**


Does aldosterone need to be high in PA?

- Consider effects of medication
- What is high?
- Normal aldosterone (<416 pmol/L) in several studies:
 - 27/74 patients with definite PA on biochemical testing
 - 16/37 patients in another study
 - 4/21 with unilateral aldosterone excess proven on adrenal vein sampling (AVS)

The myths of Primary Aldosteronism (PA)?


- PA is a rare cause of hypertension
- Serum potassium must be normal
- Plasma aldosterone must be elevated
- Making the diagnosis doesn't matter- just lower the blood pressure!

Multiple end organ effects of aldosterone excess



Increased cardiovascular morbidity in Primary Aldosteronism

Milliez *et al*, *JACC* 2005, 45, 1243-8






Aldosterone and cardiovascular complications


Table 3. Published Series on Primary Aldosteronism and Cardiovascular Complications

Published Series	Number of patients		Blood Pressure		Conclusions
	Cases	Controls	Cases	Controls	
Takeda et al ²⁵	224 patients with surgically proven APA	224 sex- and age-matched patients with EH	170±26/94±15	179±25/106±17	Myocardial infarction (1.8% vs 4.0%) Heart failure (3.6% vs 4.0%)
Milliez et al ⁴	124 patients with PA	465 patients with EH of similar age, sex, and BP	176±23/107±14	174±20/106±14	Myocardial infarction (4.0% vs 0.6%; OR, 6.5) Atrial fibrillation (7.3% vs 0.6%; OR, 12.1)
Catena et al ²⁷	54 patients with PA	323 patients with EH of similar age, sex, BMI, severity, and duration of HTN	167±16/103±9	166±18/103±8	Cardiovascular events more frequent in PA patients (35% vs 11%; OR, 4.61; <i>P</i> <0.001) Sustained arrhythmia (15% vs 3%; OR, 4.93) Cerebrovascular events (11% vs 3%; OR, 4.36) Coronary heart disease (20% vs 8%; OR, 2.80)
Current study	459 patients with PA	1290 patients with EH matched for age, sex, and BP	151±24/88±13	150±22/87±13	Myocardial infarction (4.4% vs 1.7%; OR, 2.8) Atrial fibrillation (3.9% vs 1.1%; OR, 4.3) Coronary artery disease (5.7% vs 2.8%; OR, 2.2) Heart failure (4.1% vs 1.2%; OR, 3.5)

PA and cardio/cerebrovascular events



Myocardial fibrosis more common in PA versus EH patients




Genetic aspects of aldosterone excess

Inherited aldosterone excess syndromes

- Familial hyperaldosteronism type I
 - Glucocorticoid remediable aldosteronism (GRA)
- Familial hyperaldosteronism type II
- Familial hyperaldosteronism type III

Glucocorticoid remediable aldosteronism (FH I)




- ACTH dependent aldosterone excess
- Autosomal dominant
- Severe hypertension in early life; hypokalaemia worsened by thiazide
- PCR to diagnose
- Treat with MR blockade or small dose of glucocorticoid

Familial hyperaldosteronism type II


- Family history of PA, either APA or bilateral hyperplasia
 - Need 2 or more affected first-degree relatives
- Indistinguishable from non-familial PA
- Probably autosomal dominant
- Genetic basis unclear
 - Linkage has identified area on chromosome 7p22

Familial hyperaldosteronism type III



- Severe, refractory hypertension in childhood
- Massive bilateral adrenal hyperplasia
- Bilateral adrenalectomy curative
- Rare, AD
- Genetic basis recently described: KCNJ5 gene mutations

K channel mutations in FH III




KCNJ5 mutations summary

Author	Year	Number of APA	% somatic mutations	mutations
Choi et al	2011	22	41	G151R L168R
Boukron et al	2012	380	35	G151R L168R
Akerstrom et al	2012	351	47	G151R L168R E145Q
Azizan et al	2012	73	41	G151R L168R Ile157del
Monticone et al	2012	47	38	G151R L168R
Mulatero et al	2012	46 (familial PA)	7	G151R L168R T158A

The genetics of APA

- Somatic mutations in KCNJ5 identified in aldosterone producing adenomas
- Mutant APA are larger and more common in women
- All cluster around selectivity filter of K⁺ channel pore
- Also evidence of ↑ CYP11B2 expression and aldosterone production




Other somatic mutations in APA

- ATP1A1
 - $\alpha 1$ subunit of Na/K-ATPase
 - Prevalence of 5.2%
- ATP2B3
 - Plasma membrane Ca-ATPase
 - Prevalence of 1.6%
- CACNA1D
 - L-type Ca^{2+} channel
 - Prevalence of 11%

All lead to increased intracellular Ca^{2+} .

miRNA-24 in normal adrenals vs APA




Robertson *et al.* Hypertension (2013);62(3):572-8.


Role of micro RNA in modulation of aldosterone production

H295R cells

CYP11B2 mRNA



Aldosterone



Decreased expression of miRNA-24 may contribute to increased aldosterone production in APA

Just another case of hypertension.....?

- 38 y female
- 6 years of hypertension, well controlled on ramipril
- But now BP difficult to control (162/95 mm/Hg) despite addition of amlodipine
- UE: Na 136, K 4.1 Chl 95 Ur 4.2 Cr 68
- Plasma aldosterone (supine) 395 pmol/L, plasma renin activity (PRC) 1.2 μ IU/ml (5-44.9)
 - Aldosterone to renin ratio (ARR) **329**

Not just another case of hypertension!



270

on no

Summary

- Primary Aldosteronism found in 10% of ‘essential’ hypertension
 - Hypokalaemia in < 50%
 - Plasma aldosterone not necessarily elevated
- Aldosterone has deleterious effects independent of blood pressure
- Familial PA is rare
- Identification of common somatic mutations in APA provide novel therapeutic targets as well as insight into pathophysiology